Frequently Asked Questions

What is adult stem cell therapy?

At Okyanos (The Bahamas), patients’ own adipose-derived stem and regenerative cells (ADRCs) are delivered both systemically and directly to areas of damage in the body. Among many other functions relevant to addressing different types of chronic conditions, ADRCs are known to be able to repair and replace damaged tissue, reduce inflammation, and restore blood flow.

Why use stem cells from adipose (fat) tissue and not bone marrow?

Adipose contains up to 2,500 times more stem and regenerative cells than bone marrow, is more abundant, more quickly obtained and processed to a therapeutic dose using advanced lipoaspirate technology. Stem cell extraction from bone marrow is much more painful and can take weeks to process.

Why in The Bahamas?

The Bahamas are a medically regulated jurisdiction with a strong focus on safety coupled with a commitment to accelerating medical care and innovation for patients under careful oversight. Regenerative medicine and stem cell therapies remain highly unregulated throughout the world. For patients this translates to insufficient safety standards, zero facility inspection and no oversight of the resultant cell product(s) for purity and viability. Okyanos is proud to have been the first cell therapy facility to receive approval from The Bahamas National Stem Cell Ethics Committee (NSCEC) under legislation passed in 2013 which allows and regulates the use of patients’ own adult stem cells in the treatment of certain chronic conditions. In order to maintain accreditation, Okyanos has routine regulatory oversight and inspection to ensure safety.

What are the risks of treatment?

The risks of stem cell therapy are minimal. Okyanos therapies have been shown to be safe and efficacious in scientific and/or medical literature for the conditions they treat, and there have been zero reports of cell-related adverse effects using a patient’s own adipose-derived stem and regenerative cells (ADRCs). Further, because these cells are a patient’s own the risk of cell rejection is eliminated.